Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
  • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
  • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
  • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the atypical antipsychotics Compared to the first generation antipsychotics, the atypical antipsychotics appear to be equally effective in reducing the positive symptoms like hallucinations and delusions but may be better than the typical antipsychotics at relieving the negative symptoms of schizophrenia such as apathy, withdrawal, emotional depression and the like.
• the atypical antipsychotics currently in clinical use include Aripiprazole (ABILIFY®), clozapine (CLOZARIL®), risperidone (RISPERDAL®), olanzapine (ZYPREXA®), quetiapine (SEROQUEL®), and ziprasidone (GEODON®).
• Atypical antipsychotics have diminished propensity to cause extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) than typical antipsychotics. Additional benefits associated with the atypical antipsychotics include better treatment of negative symptoms, better compliance, possible benefits for cognitive impairments, and lower rates of relapse. Within the class of atypical antipsychotics, however, differences exist both in efficacy and side effects. Clozapine does not cause EPS, and is clearly more effective than all other antipsychotics used in humans to date. It is however a life-altering drug, because of its side effects and need for continual medical monitoring, in some countries, for agranulocytosis. This has markedly limited its use.
• risperidone and olanzapine are the most commonly used first-line antipsychotics today. This is warranted because they are more clinically effective than conventional drugs and much easier to use than clozapine. However, both risperidone and olanzapine are limited by side effects. Risperidone causes prolactin elevations, weight gain and dose-dependant EPS. Olanzapine use is associated with much more weight gain in addition to lipid and glucose abnormalities.
• the present invention provides quinazolinedione derivatives comprising compounds of Formula (1):
• A is -(CH 2 ) n - -O-(CH 2 ) n -, -S-(CH 2 ) n -, -S(O)(O)-(CH 2 ) n -, -NH-(CH 2 ) n -, -CH 2 -O-(CH 2 ) n -, - (CH 2 VO-CH 2 -CH 2 -, -CH 2 -S-(CH 2 V, -(CH 2 VS-CH 2 -CH 2 -, -CH 2 -S(O)(O)-(CH 2 V, - (CH 2 VS(O)(O)-CH 2 -CH 2 -, -0-C(O)-(CH 2 V, -S-C(O)-(CH 2 V, -NH-C(O)-(CH 2 V, - CH 2 -C(O)-O-(CH 2 V, -CH 2 -C(O)-NH-
• R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is each independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, acylalkyloxycarbonyl, acyloxyalkyloxycarbonyl, acylalkyloxycarbonylamino, acyloxyalkyloxycarbonylamino, alkoxy, alkoxycarbonyl, alkoxycarbonylalkoxy, alkoxycarbonyllalkylamino, alkylasulf ⁇ nyl, alkylsulfonyl, alkylthio, amino, alkylamino, aryl
• compositions comprising the compounds of the present disclosure.
• methods of treating one of psychoses, schizophrenia, acute mania, bipolar disorder, autistic disorder or depression comprising administering to a patient in need thereof the compounds of the present disclosure.
• compounds of the present disclosure are used for the treatment of any one of psychoses, schizophrenia, acute mania, bipolar disorder, autistic disorder or depression.
• compounds of the present disclosure are used in the manufacture of a medicament for use in treatment of one of psychoses, schizophrenia, acute mania, bipolar disorder, autistic disorder or depression.
• the present invention relates to synthesis, compositions and methods of using quinazolinedione derivatives which are useful for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, depression and dementia.
• the present invention provides compounds, compositions and methods for pharmacological treatment of schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, depression and dementia.
• Compounds of the invention refers to compounds encompassed by structural Formula (1) as disclosed herein.
• the compounds of the invention can be identified either by their chemical structure and/or chemical name. When the chemical structure and chemical name conflict, the chemical structures is determinative of the identity of the compound.
• the compounds of the invention may contain one or more chiral centers and/or double bonds and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers or diastereoisomers.
• the chemical structures depicted herein encompass all possible enantiomers and stereoisomers of the illustrated compounds including the stereoisomerically pure form (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures.
• Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan.
• the compounds of the invention may also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds.
• the compounds of the invention also include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass of conventionally found in nature.
• isotopes that may be incorporated into the compounds of the invention include, but are not limited to 2 H, 3 H, 13 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F and 36 Cl. Further, it should be understood, when partial structures of the compounds of the invention are illustrated, that brackets of dashes indicate the point of attachment of the partial structure to the rest of the molecule.
• composition of the invention refers to at least one compound of the invention and a pharmaceutically acceptable vehicle, with which the compound is administered to a patient.
• the compounds of the invention are administered is isolated form, which means separated from a synthetic organic reaction mixture.
• Alkyl refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne.
• Typical alkyl groups include, but are not limited to methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2yl, cyclopropan-1-yl, prop-1-en-l-yl, prop-l-en-2-yl, prop-2-en-l-yl (allyl), cycloprop-1-en-lyl, cycloprop-2-en-lyl, prop-1-yn-l-yl, prop-2-yn-l-yl, etc.; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-l-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but-1- en-l-yl, but-l-en-2-yl, 2-methyl-prop-l-en-l-yl, but-2-en-2-yl, but-2-en-2
• alkyl specifically intended to include radicals having any degree or level of saturation, i.e., groups having exclusively single carbon-carbon bonds, groups having one or more double carbon-carbon bonds, groups having one or more triple carbon-carbon bonds and groups having mixtures of single, double and triple carbon-carbon bonds.
• alkanyl alkenyl
• alkynyl alkynyl
• an alkyl group comprises from 1-20 carbon atoms, more preferably, from 1 to 10 carbon atoms.
• alkanyl refers to a saturated branched, straight-chain or cyclic alkyl radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane.
• Typical alkanyl groups include but are not limited to , methanyl; ethanyl; propanyls such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl, etc.; butanyls such as butan-1-yl, butan-2-yl (sec-butyl), 2-methyl-propan-l-yl (isobutyl), 2-methyl-propan-2-yl (t-butyl), cyclobutan-1-yl, etc.; and the like.
• Alkenyl refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene.
• the group may be in either the cis or trans conformation about the double bond(s).
• Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-l-yl, prop-l-en-2-yl, prop-2-en-l-yl (allyl), prop-2- en-2-yl, cycloprop-1-en-l-yl, cycloprop-2-en-l-yl; butenyls such as but-1-en-l-yl, but-l-en- 2-yl, 2-methy-prop-l-en-l-yl, but-2-en-l-yl, but-2-en-2-yl, buta-l,3-dien-l-yl, buta-l,3-dien- 2-yl, cyclobut-1-en-l-yl, cyclobut-l-en-3-yl, cyclobuta-l,3-dien 1-yl, etc.; and the like.
• Alkynyl refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne.
• Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop- 1-yn- 1-yl, prop-2-yn-l-yl, etc.; butynyls such as but- 1-yn- 1-yl, but-l-yn3-yl, but-3-yn-l-yl, etc.; and the like.
• Acyl refers to a radical — C(O)R, where R is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like.
• Acyloxyalkyloxycarbonyl refers to a radical -C(O)OCR'R"OC(O)R"', where R', R", and R"' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but not limited to -C(O)OCH 2 OC(O)CH 3 , -C(O)OCH 2 OC(O)CH 2 CH 3 , - C(O)OCH(CH 3 )OC(O)CH 2 CH 3 , -C(O)OCH(CH 3 )OC(O)C 6 H 5 and the like.
• Acylalkyloxycarbonyl refers to a radical -C(O)OCR'R"C(O)R'", where R', R", and R' ' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but not limited to -C(O)OCH 2 C(O)CH 3 , -C(O)OCH 2 C(O)CH 2 CH 3 , -C(O)OCH(CH 3 )C(O)CH 2 CH 3 , -C(O)OCH(CH 3 )C(O)C 6 H 5 and the like.
• R, R', R", and R"' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but not limited to -NHC(O)OCH 2 OC(O)CH 3 , - NHC(O)OCH 2 OC(O)CH 2 CH 3 , -NHC(O)OCH(CH 3 )OC(O)CH 2 CH 3 , - NHC(O)OCH(CH 3 )OC(O)C 6 H 5 and the like.
• Acylalkyloxycarbonylamino refers to a radical -NRC(O)OCR'R"C(O)R"', where R, R', R", and R'" are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but not limited to -NHC(O)OCH 2 C(O)CH 3 , - NHC(O)OCH 2 C(O)CH 2 CH 3 , -NHC(O)OCH(CH 3 )C(O)CH 2 CH 3 , - NHC(O)OCH(CH 3 )C(O)C 6 H 5 and the like.
• Alkylamino means a radical — NHR where R represents an alkyl, or cycloalkyl group as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to, methylamino, ethylamino, 1-methylethylamino, cyclohexylamino and the like.
• Alkoxy refers to a radical — OR where R represents an alkyl, or cycloalkyl group as defined herein that may be optionally substituted by one or more substituents as defined herein. Representative examples include, but are not limited to methoxy, ethoxy, propoxy, butoxy, cyclohexyloxy and the like.
• Alkoxycarbonyl refers to a radical — C(O)-alkoxy where alkoxy is as defined herein.
• Alkoxycarbonylalkoxy refers to a radical — OCR'R"C(O)-alkoxy where alkoxy is as defined herein.
• R' and R" are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to — OCH 2 C(O)OCH 3 , -OCH 2 C(O)OCH 2 CH 3 , -OCH(CH 3 )C(O)OCH 2 CH 3 , -OCH(C 6 H 5 )C(O)OCH 2 CH 3 , -OCH(CH 2 C 6 H 5 )C(O)OCH 2 CH 3 , -OC(CH 3 )(CH 3 )C(O)OCH 2 CH 3 , and the like.
• Alkoxycarbonylalkylamino refers to a radical — NRCR'R' ' C(O)-alkoxy where alkoxy is as defined herein.
• R, R', R' and R" are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to -NHCH 2 C(O)OCH 3 , -N(CH 3 )CH 2 C(O)OCH 2 CH 3 , -NHCH(CH 3 )C(O)OCH 2 CH 3 , -NHCH(C 6 H 5 )C(O)OCH 2 CH 35 -NHCH(CH 2 C 6 H 5 )C(O)OCH 2 CH 3 , -NHC(CH 3 )(CH 3 )C(O)OCH 2 CH 3 , and the like.
• Alkylsulfonyl refers to a radical — S(O) 2 R where R is an alkyl, or cycloalkyl group as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, and the like.
• Alkylsulfmyl refers to a radical — S(O)R where R is an alkyl, or cycloalkyl group as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to, methylsulfinyl, ethylsulf ⁇ nyl, propylsulf ⁇ nyl, butylsulf ⁇ nyl, and the like.
• Alkylthio refers to a radical — SR where R is an alkyl or cycloalkyl group as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to methylthio, ethylthio, propylthio, butylthio, and the like.
• Amide or "acylamino” refers to a radical — NR'C(0)R' ' , where R' and R' ' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to, formylamino acetylamino, cyclohexylcarbonylamino, cyclohexylmethylcarbonyl-amino, benzoylamino, benzylcarbonylamino and the like.
• Aryl refers to a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
• Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorine, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleidene
• an aryl group comprises from 6 to 20 carbon atoms, more preferably, between 6 to 12 carbon atoms.
• Arylalkyl refers to an acyclic alkyl in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp carbon atom, is replaced with an aryl group.
• arylalkyl groups include, but not limited to, benzyl, 2-phenylethan-l-yl, 2- phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-l-yl, 2-naphthylethene-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like.
• arylalkany, arylalkenyl and/or arylalkynyl is used.
• an arylalkyl group is (C 6 -C 3 o)arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C 1 -C 10 ) and the aryl moiety is (C 6 -C 2 O), more preferably, an arylalkyl group is (C 6 -C 2 O) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C 1 -C 8 ) and the aryl moiety is (C 6 -Ci 2 ).
• Arylalkoxy refers to an — O-arylalkyl radical where arylalkyl is as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Arylalkoxycarbonylalkoxy refers to a radical — OCR'R"C(O)-arylalkoxy where arylalkoxy is as defined herein.
• R' and R' ' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to -OCH 2 C(O)OCH 2 C 6 H 55 -OCH(CH 3 )C(O)O CH 2 C 6 H 55 -OCH(C 6 H 5 )C(O)O CH 2 C 6 H 5 , -OCH(CH 2 C 6 H 5 )C(O)O CH 2 C 6 H 55 -OC(CH 3 )(CH 3 )C(O)O CH 2 C 6 H 5 , and the like.
• Arylalkoxycarbonylalkylamino refers to a radical — NRCR'R' ' C(O)-arylalkoxy where arylalkoxy is as defined herein.
• R, R', R' and R" are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to -NHCH 2 C(O)OCH 2 C 6 H 55 -N(CH 3 )CH 2 C(O)OCH 2 C 6 H 55 -NHCH(CH 3 )C(O)OCH 2 C 6 H 5 , -NHCH(C 6 H 5 )C(O)OCH 2 C 6 H 55 -NHCH(CH 2 C 6 H 5 )C(O)OCH 2 C 6 H 55 -NHC(CH 3 )(CH 3 )C(O)OCH 2 C 6 H 55 and the like.
• Aryloxycarbonyl refers to radical — C(O)-O-aryl where aryl is defined herein that may be optionally substituted by one or more substituents as defined herein.
• Aryloxycarbonylalkoxy refers to a radical — OCR'R' 'C(O)-aryloxy where aryloxy is as defined herein.
• R' and R' ' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to — OCH 2 C(O)OCeHs, -OCH(CH 3 )C(O)OC 6 H 5 , -OCH(C 6 H 5 )C(O)OC 6 H 5 , -OCH(CH 2 C 6 H 5 )C(O)OC 6 H 5 , -OC(CH 3 )(CH 3 )C(O)OC 6 H 5 , and the like.
• Aryloxycarbonylalkylamino refers to a radical — NRCR'R"C(O)-aryloxy where aryloxy is as defined herein.
• R, R', R' and R" are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to -NHCH 2 C(O)OC 6 H 5 , -N(CH 3 )CH 2 C(O)OC 6 H 5 , -NHCH(CH 3 )C(O)OC 6 H 5 , -NHCH(C 6 H 5 )C(O)OC 6 H 55 -NHCH(CH 2 C 6 H 5 )C(O)OC 6 H 5 , -NHC(CH 3 )(CH 3 )C(O)OC 6 H 5 , and the like.
• Carbamoyl refers to the radical — C(O)NRR where each R group is independently, hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Carbamate refers to a radical -NR' C(O)OR", where R' and R' ' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to, methylcarbamate (-NHC(O)OCH 3 ), ethylcarbamate (-NHC(O)OCH 2 CH 3 ), benzylcarbamate (-NHC(O)OCH 2 C 6 H 5 ), and the like.
• Carbonate refers to a radical — OC(O)OR, where R is alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to, methyl carbonate ( — C(O)OCH 3 ), cyclohexyl carbonate ( — C(O)OC 6 Hn), phenyl carbonate ( — C(O)OC 6 H 5 ), benzyl carbonate (-C(O)OCH 2 C 6 H 5 ), and the like.
• Carboxy means the radical — C(O)OH.
• Cyano means the radical — CN.
• Cycloalkyl refers to a substituted or unsubstituted cylic alkyl radical. Where a specific level of saturation is intended, the nomenclature “cycloalkanyl” or “cycloalkenyl” is used. Typical cycloalkyl groups include, but are not limited to, groups derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane, and the like. In a preferred embodiment, the cycloalkyl group is (C 3 -C 10 ) cycloalkyl, more preferably (C 3 -C 7 ) cycloalkyl.
• Cycloheteroalkyl refers to a saturated or unsaturated cyclic alkyl radical in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatom.
• Typical heteroatoms to replace the carbon atom(s) include, but are not limited to, N, P, O, S, Si, etc. Where a specific level of saturation is intended, the nomenclature “cycloheteroalkanyl” or “cycloheteroalkenyl” is used.
• Typical cycloheteroalkyl groups include, but are not limited to, groups derived from epoxides, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, and the like.
• Cycloheteroalkoxycarbonyl refers to a radical — C(O) — OR where R is cycloheteroalkyl as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Dialkylamino means a radical — NRR' where R and R' independently represent an alkyl or cycloalkyl group as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to dimethylamino, methylethylamino, di-(l-methylethyl)amino, (cyclohexyl)(methyl)amino, (cyclohexyl)(ethyl)amino, (cyclohexyl)(propyl)amino, and the like.
• “Derived from a drug” refers to a fragment that is structurally related to such a drug.
• the structure of the fragment is identical to the drug except where a hydrogen atom attached to a heteroatom (N or O) has been replaced with a covalent bond to another group (typically, a promoiety).
• a drug is a salt form of a carboxylic, phosphonic or phosphoric acid
• the corresponding structural fragment derived from such a drug is considered to be derived from the protonated acid form.
• “Drug” refers to a compound that exhibits therapeutic and/or prophylactic and/or diagnostic utility when administered in effective amounts to a patient or a mammal.
• “Ester” refers to a radical — C(O)OR, where R is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Representative examples include, but are not limited to, methyl ester ( — C(O)OCH 3 ), cyclohexyl ester ( — C(O)OC 6 Hn), phenyl ester ( — C(O)OC 6 H 5 ), benzyl ester (-C(O)OCH 2 C 6 H 5 ), and the like.
• Ether refers to a radical — OR, where R is alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Halo means fluoro, chloro, bromo, or iodo.
• Heteroalkoxy means an — O-heteroalkyl radical where heteroalkyl is as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Heteroalkyl, Heteroalkanyl, Heteroalkenyl, Heteroalkynyl refer to alkyl, alkanyl, alkenyl and alkynyl groups, respectively, in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic groups.
• Typical heteroatomic groups include, but are not limited to — O — ,
• N N- NR'- ,— PH- , -P(O) 2 -, — O— P(O) — , -S(O-, -S(O) 2 -, -SnH 2 -, and the like, wherein R' is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl or substituted aryl that may be optionally substituted by one or more substituents as defined herein.
• Heteroaryl refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system.
• Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arsindole, carbazole, carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyrid
• the heteroaryl group is between 5-20 membered heteroaryl, with 5-10 membered heteroaryl being particularly preferred.
• Preferred heteroaryl groups are those derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.
• Heteroaryloxycarbonyl refers to a radical — C(O) — OR where R is heteroaryl as defined that may be optionally substituted by one or more substituents as defined herein.
• Heteroarylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylalkenyl and/or heteroarylalkynyl is used.
• the heteroarylalkyl radical is a 6-30 carbon membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-10 membered and the heteroaryl moiety is a 5- 20 membered heteroaryl, more preferably, a 6-20 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-8 membered and the heteroaryl moiety is a 5-12 membered heteroaryl.
• Haldroxy means the radical — OH.
• the term "patient” encompasses mammals and non-mammals.
• mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
• non-mammals include, but are not limited to, birds, fish and the like. The term does not denote a particular age or gender.
• “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
• “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention, which is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound.
• Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentane propionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4- hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,
• “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.
• Phosphate refers to a radical — OP(O)(OR' )(OR' '), where R' and R' ' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Phosphonate refers to a radical — P(O)(OR')(OR' '), where R' and R' ' are each independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Preventing refers to a reduction in risk of acquiring a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).
• Protecting group refers to a group of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in Green et al., “Protective Groups in Organic Chemistry", (Wiley, 2 nd ed. 1991) and Harrison et al., “Compendium of Synthetic Organic Methods", vols. 1-8 (John Wiley and Sons, 1971-1996).
• Representative amino protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilyl-ethanesulfonyl (“SES”), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxy-carbonyl (“FMOC”), nitroveratryloxycarbonyl (“NVOC”) and the like.
• Representative hydroxyl protecting groups include, but are not limited to, those where the hydroxyl group is either acylated or alkylated such as benzyl, and trialkylsilyl ethers and allyl ethers.
• Racemate refers to an equimolar mixture of enantiomers of a chiral molecule.
• Substituted refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituents(s).
• Sulfate refers to a radical — OS(O)(O)OR, where R is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• S(0)(0)NR'R a radical — S(0)(0)NR'R
• R' and R are independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein or optionally R' and R" together with the atom to which they are both attached form a cycloheteroalkyl or substituted cycloheteroalkyl ring.
• Representative examples include but not limited to azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, 4-(NR'")-piperazinyl or imidazolyl group wherein said group may be optionally substituted by one or more substituents as defined herein.
• R'" hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• S(O)(O)OR refers to a radical — S(O)(O)OR, where R is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Thio means the radical — SH.
• Thioether refers to a radical — SR, where R is alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, as defined herein that may be optionally substituted by one or more substituents as defined herein.
• Treating” or “Treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
• treating or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the patient.
• “treating” or “treatment” refers to inhibiting the disease or disorder, either physically (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
• “treating” or “treatment” refers to delaying the onset of the disease or disorder.
• “Therapeutically effective amount” means the amount of a compound that, when administered to a patient for treating a disease, is sufficient to effect such treatment for the disease.
• the “therapeutically effective amount” will vary depending on the compound, the disease and is severity and the age, weight, etc., of the patient to be treated, and can be determined by one of skill in the art without undue experimentation.
• the present invention provides quinazolinedione derivatives comprising compounds of Formula (1):
• A is -(CH 2 ) n - -O-(CH 2 ) n -, -S-(CH 2 ) n -, -S(O)(O)-(CH 2 V, -NH-(CH 2 V, -CH 2 -O-(CH 2 V, - (CH 2 VO-CH 2 -CH 2 -, -CH 2 -S-(CH 2 V, -(CH 2 VS-CH 2 -CH 2 -, -CH 2 -S(O)(O)-(CH 2 V, - (CH 2 VS(O)(O)-CH 2 -CH 2 -, -0-C(O)-(CH 2 V, -S-C(O)-(CH 2 V, -NH-C(O)-(CH 2 V, - CH 2 -C(O)-O-(CH 2 V, -CH 2 -C(O)-NH-(CH 2 V, -CH 2 -C(O)
• R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is each independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, acylalkyloxycarbonyl, acyloxyalkyloxycarbonyl, acylalkyloxycarbonylamino, acyloxyalkyloxycarbonylamino, alkoxy, alkoxycarbonyl, alkoxycarbonylalkoxy, alkoxycarbonyllalkylamino, alkylasulfinyl, alkylsulfonyl, alkylthio, amino, alkylamino, arylal
• A is -O-(CH 2 ) n -, -S-(CH 2 ),,-. -CH 2 -O-(CH 2 ),,-, - (CH 2 VO-CH 2 -CH 2 -, -CH 2 -S-(CH 2 V, or -(CH 2 VS-CH 2 -CH 2 -.
• A is -NH-C(O)-(CH 2 V, -CH 2 -NH-C(O)- (CH 2 V, -CH 2 -C(O)-NH-(CH 2 V or -(CH 2 VC(O)-NH-CH 2 -CH 2 -.
• Compounds of the invention can have affinity for dopamine D 2 receptors
• Compounds of the invention can have affinity for serotonin 5-HT IA receptors
• Compounds of the invention can have affinity for serotonin 5-HT 2 A receptors
• HERG human ether-a- go-go related gene
• Oral bioavailability of the compounds is consistent with oral administration using standard pharmacological oral formulations; however, the compounds, and compositions thereof, can also be administered using any delivery system that produces constant and controllable blood levels overt time.
• the invention provides compounds having any two or more of the above-identified characteristics or properties. In another aspect, the invention provides for compounds having at least any three or more of the above-identified properties or characteristics. Preferably, the compounds of the invention have all seven characteristics or properties.
• analogs and salts of the exemplified compounds are within the scope of the subject invention.
• skilled artisans can use known procedures to synthesize these compounds from available substrates.
• analogs refers to compounds which are substantially the same as another compound but which may have been modified by, for example, adding additional side groups.
• analogs as used in this application also may refer to compounds which are substantially the same as another compound but which have atomic or molecular substitution at certain locations in the compound.
• the subject invention further pertains to enantiomerically isolated compounds, and compositions comprising the compounds.
• the isolated enantiomeric forms of the compounds of the invention are substantially free from one another (i.e., in enantiomeric excess).
• the "R” forms of the compounds are substantially free from the "S” forms of the compounds and are, thus, in enantiomeric excess of the "S” forms.
• "S” forms of the compounds are substantially free of "R” forms of the compounds and are, thus, in enantiomeric excess of the "R” forms.
• the isolated enantiomeric compounds are at least about in 80% enantiomeric excess.
• the compounds are at least about 90% enantiomeric excess, preferably at least about 95% enantiomeric excess, more preferably at least about 97% enantiomeric excess, or even more preferably, at least 99% or greater than 99% enantiomeric excess.
• the compounds of the invention can be obtained via the synthetic methods illustrated in Schemes 1-2.
• Schemes 1-2 Several methods have been described in the art for the synthesis of arylpiperazine derivatives.
• the starting materials and building blocks useful for preparing compounds of the invention and intermediates thereof are commercially available or can be prepared by well-known synthetic methods (see e.g., Green et al., "Protective Groups in Organic Chemistry,"(Wiley, 4th ed., 2006); Harrison et al "Compendium of Synthetic Organic Methods," vols.
• the amide 2 was treated with aluminum chloride in anhydrous dichloromethane at reflux temperature to get the corresponding nitrophenol derivative 3.
• the compound 5 was prepared by alkylating the phenol 3 with 1 ,4-dibromobutane 4 by heating at reflux in acetone in presence of a mild base potassium carbonate (K2CO3).
• K2CO3 a mild base potassium carbonate
• the reaction of compound 5 with arylpiperazine 6 in presence of N,N-diisopropylethylamine (DIEA) in acetonitrile at approximately 60-70 C for 8 to 16 h gave the arylpiperazine derivate 7.
• DIEA N,N-diisopropylethylamine
• the compound 8 was heated with 1,1 '-carbonyldiimidazole (CDI) in N,N-dimethylformamide (DMF) to give the target quinazolinedione 9 which was converted into hydrochloride salt 10 by treating with hydrogen chloride under standard conditions.
• the quinazolinedione 9 can also be converted into other pharmaceutically acceptable salts such as methanesulfonic acid salts and lower aliphatic carboxylic acid salts using well known methods in the field.
• the amide 11 was prepared by alkylating the suitable arylpiparzine with ethyl 4-bromobutanoate using mild base diisopropylethylamine (DIEA) in polar aprotic solvent anhydrous acetonitrile.
• DIEA diisopropylethylamine
• the amide 12 was prepared heating carboxylic acid ester 11 with ammonia solution.
• the amine 12 was subjected to reduction conditions with lithium aluminum hydride (LiAlH 4 ) to give the corresponding amine 13.
• the amine 13 was coupled with anthranilic acid 14 under standard coupling conditions using DCC and N-hydroxysuccinimide (HOSu) as coupling agents to give the corresponding amide 15.
• the amide 15 was heated with CDI in DMF to give the target quinazolinedione 16 which was converted into hydrochloride salt 17 by treating with hydrogen chloride under standard conditions.
• the quinazolinedione 16 can also be converted into other pharmaceutically acceptable salts such as methanesulfonic acid salts and lower aliphatic carboxylic acid salts using well known methods in the field.
• the present invention relates to synthesis, compositions and methods of using quinazolinedione derivatives which are useful for treating schizophrenia and related psychoses such as acute maniac, bipolar disorder, autistic disorder, depression and dementia.
• the present invention provides methods for synthesizing such quinazolinedione based antipsychotic agents.
• the present invention also provides methods for using quinazolinedione based antipsychotic agents and composition of quinazolinedione based antipsychotic agents for treating schizophrenia and related psychoses such as acute maniac, bipolar disorder, autistic disorder, depression and dementia.
• compositions comprising the compounds of the present disclosure.
• a compound and/or a composition containing a compound of structural Formula (1) is administered to a patient, preferably a human, suffering from schizoprenia.
• the compounds and/or compositions of the invention are administered to a patient, preferably a human, as a treatment or preventive measure against acute manic, bipolar disorder, autistic disorder, depression and dementia.
• the compounds, and/or compositions containing compounds(s), of structural Formula (1) can be advantageously used in human medicine. As previously described in detail above, compounds and compositions containing compound(s) of structural Formula (1) are useful for the treatment of schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, depression and dementia.
• methods of treating one of psychoses, schizophrenia, acute mania, bipolar disorder, autistic disorder or depression comprising administering to a patient in need thereof the compounds of the present disclosure.
• the method treats schizophrenia.
• the method treats bipolar disorder.
• compounds of the present disclosure are used for the treatment of any one of psychoses, schizophrenia, acute mania, bipolar disorder, autistic disorder or depression.
• the use comprises the treatment of schizophrenia.
• the use comprises the treatment of bipolar disorder.
• compounds of the present disclosure are used in the manufacture of a medicament for use in treatment of one of psychoses, schizophrenia, acute mania, bipolar disorder, autistic disorder or depression.
• the use is for the treatment of schizophrenia.
• the use is for the treatment of bipolar disorder.
• compounds and/or compositions of the invention can be administered or applied singly, in combination with other agents.
• the compounds and/or compositions of the invention can also be administered or applied singly, in combination with other pharmaceutically active agents, including other compounds and/or compositions of the invention.
• the current invention provides methods of treatment and prophylaxis by administration to a patient of a therapeutically effective amount of a composition and/or compound of the invention.
• the patient may be an animal, is more preferably a mammal, and most preferably a human.
• the present compounds and/or compositions of the invention which comprise one or more compounds and/or compositions of the invention are preferably administered orally.
• the compounds and/or compositions of the invention may also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.). Administration can be systemic or local.
• Various delivery systems are known, (e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc.) that can be used to administer a compound and/or composition of the invention.
• Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravabinal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes or skin.
• the compounds and/or compositions of the invention can be delivered via sustained release systems, preferably oral sustained release systems.
• a pump may be used (see, Langer, supra; Sefton, 1987, CRC Crit. Ref Biomed. Eng. 14:201; Saudek et al, 1989, N. Engl. J. Med. 321 :574).
• polymeric materials can be used (see “Medical Applications of Controlled Release,” Langer and Wise (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol Chem. 23:61; see also Levy et al, 1985, Science 228:190; During et al, 1989, Ann. Neural. 25:351; Howard et al, 1989, J. Neurosurg. 71 : 105).
• polymeric materials are used for oral sustained release delivery.
• Preferred polymers include sodium carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose and hydroxyethylcellulose (most preferred, hydroxypropylmethylcellulose).
• Other preferred cellulose ethers have been described in the art (Bamba et al., Int. J. Pharm., 1979, 2, 307).
• enteric-coated preparations can be used for oral sustained release administration.
• Preferred coating materials include polymers with a pH-dependent solubility (i.e., pH-controlled release), polymers with a slow or pH-dependent rate of swelling, dissolution or erosion (i.e., time controlled release), polymers that are degraded by enzymes (i.e., enzyme controlled release) and polymers that form firm layers that are destroyed by an increase in pressure (i.e., pressure-controlled release).
• osmotic delivery systems are used for oral sustained release administration (Verma et al., Drug Dev. Ind. Pharm., 2000, 26:695-708).
• OROS® osmotic delivery systems are used for oral sustained release delivery devices (See for example, Theeuwes et al., U.S. Pat. No. 3,845,770; and Theeuwes et al , U.S. Pat. No. 3,916,899).
• a controlled-release system can be placed in proximity of the target of the compounds and/or composition of the invention, thus requiring only a fraction of the systemic dose (See, e.g., Goodson, in "Medical Applications of Controlled Release,” supra, vol. 2, pp. 115-138 (1984)).
• Other controlled-release systems discussed in Langer, 1990, Science 249:1527-1533 may also be used.
• the compounds, and/or compositions containing compound(s) of structural Formula (1) of the invention may be cleaved either chemically and/or enzymatically.
• One or more enzymes present in the stomach, intestinal lumen, intestinal tissue, blood, liver, brain or any other suitable tissue of a mammal may enzymatically cleave the compounds and/or compositions of the invention.
• compositions comprising the compounds of the present disclosure.
• the present composition contain a therapeutically effective amount of one or more compounds of the invention, preferably in purified form, together with a suitable amount of a pharmaceutically acceptable vehicle, which so as to provide the form for proper administration to a patient.
• a pharmaceutically acceptable vehicle which so as to provide the form for proper administration to a patient.
• the compounds of the invention and pharmaceutically acceptable vehicles are preferably sterile. Water is preferred vehicle when the compound of the invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions.
• Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
• excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
• present agents or pH buffering agents.
• auxiliary, stabilizing, thickening, lubricating and coloring agents may be used.
• compositions comprising a compound of the invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making levigating, and emulsifying, encapsulating, entrapping or lyophilizing process.
• Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries, which facilitate processing of compounds of the invention into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
• compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, and capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use.
• the pharmaceutically acceptable vehicle is a capsule (see e.g., Grosswald et al, U.S.Pat. No. 5,698,155).
• suitable pharmaceutical vehicles have been described in the art (see Remington's Pharmaceutical Sciences, Philadelphia College of Pharmacy and Science, 17 th Edition, 1985).
• Preferred compositions of the invention are formulated for oral delivery, particularly for oral sustained release administration.
• compositions for oral delivery may be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups or elixirs, for example.
• Orally administered compositions may contain one or more optionally agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry coloring agents and preserving agents to provide a pharmaceutically palatable preparation.
• sweetening agents such as fructose, aspartame or saccharin
• flavoring agents such as peppermint, oil of wintergreen, or cherry coloring agents and preserving agents to provide a pharmaceutically palatable preparation.
• the compositions may be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time.
• Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compounds of the invention.
• fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture.
• delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations.
• a time delay material such as glycerol monostearate or glycerol stearate may also be used.
• Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such vehicles are preferably of pharmaceutical grade.
• suitable carriers, excipients or diluents include water , saline, alkyleneglycols (e.g., propylene glycol), polyalkylene glycols (e.g., polyethylene glycol) oils, alcohols, slightly acidic buffers between pH 4 and pH 6 (e.g., acetate, citrate, ascorbate at between about mM to about 50 mM) etc.
• alkyleneglycols e.g., propylene glycol
• polyalkylene glycols e.g., polyethylene glycol
• slightly acidic buffers between pH 4 and pH 6 e.g., acetate, citrate, ascorbate at between about mM to about 50 mM
• flavoring agents, preservatives, coloring agents, bile salts, acylcamitines and the like may be added.
• compositions for administration via other routes may also be contemplated.
• buccal administration the compositions may take the form of tablets, lozenzes, etc. formulated in conventional manner.
• Liquid drug formulations suitable for use with nebulizers and liquid spray devices and EHD aerosol devices will typically include a compound of the invention with a pharmaceutically acceptable vehicle.
• the pharmaceutically acceptable vehicle is a liquid such as alcohol, water, polyethylene glycol or a perfluorocarbon.
• another material may be added to alter the aerosol properties of the solution or suspension of compounds of the invention.
• this material is liquid such as alcohol, glycol, polyglycol or fatty acid.
• a compound of the invention may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa, butter or other glycerides.
• a compound of the invention may also be formulated as depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
• a compound of the invention may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• a compound of the invention when it is acidic, it may be included in any of the above-described formulations as the free acid, a pharmaceutically acceptable salt, a solvate or hydrate.
• Pharmaceutically acceptable salts substantially retain the activity of the free acid, may be prepared by reaction with bases and tend to be more soluble in aqueous and other protic solvents than the corresponding free acid form.
• a compound of the invention, or compositions thereof, will generally be used in an amount effective to achieve the intended purpose.
• schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.
• the compounds of Formula (1) and compositions containing a compound of Formula (1) are administered or applied in a therapeutically effective amount.
• the amount of a compound of the invention that will be effective in the treatment of a particular disorder or condition disclosed herein will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques known in the art as previously described. In addition, in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges.
• the amount of a compound of the invention administered will, of course, is dependent on, among other factors, the subject being treated, and the weight of the subject, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
• the dosage may be delivered in a pharmaceutical composition by a single administration, by multiple applications or controlled release.
• the compounds of the invention are delivered by oral sustained release administration.
• the compounds of the invention are administered twice per day, and more preferably, once per day. Dosing may be repeated intermittently, may be provided alone or in combination with other drugs and may continue as long as required for effective treatment of the disease state or disorder.
• the compounds and/or compositions containing compound(s), of structural Formula (1) for the pharmacological treatment of schizophrenia and related psychoses such as acute maniac, bipolar disorder, autistic disorder and depression may be administered in the range 0.1 mg to 500 mg preferably 1 mg to 100 mg per day given in one or more doses and more preferably 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 35 mg or 50 mg per day and most preferably 10 mg.
• the compounds of the invention are preferably assayed in vitro and in vivo, for the desired therapeutic or prophylactic activity, prior to use in humans.
• the compounds of the invention may also be demonstrated to be effective and safe using animal model systems.
• the therapeutically effective dose of a compound of the invention described herein will provide therapeutic benefit without causing substantial toxicity.
• Toxicity of compounds of the invention may be determined using standard pharmaceutical procedures and may be readily ascertained by the skilled artisan.
• the dose ratio between toxic and therapeutic effect is the therapeutic index.
• a compound of the invention will preferably exhibit particularly high therapeutic indices in treating disease and disorders.
• the dosage of a compound of the inventions described herein will preferably be within a range of circulating concentrations that include an effective dose with little or no toxicity.
• the compounds of the invention can be used in combination therapy with at least one other therapeutic agent.
• the compound of the invention and the therapeutic agent can act additively or, more preferably, synergistically.
• composition comprising a compound of the invention is administered concurrently with the administration of another therapeutic agent, which can be part of the same composition.
• a composition comprising a compound of the invention is administered prior or subsequent to administration of another therapeutic agent.
• CDI 1 , 1 '-Carbonyldiimidazole
• nM nanomolar
• ⁇ M micromolar
• Receptor Source Human recombinant expressed in CHO cells
• Radioligand [ 3 H] Spiperone (20-60 Ci/mmol)
• the reaction was terminated by rapid vacuum filtration onto glass fiber filters. Radioactivity trapped onto the filters was determined and compared to control values in order to ascertain any interactions of test compounds with the cloned dopamine - D 2 short binding site
• Receptor Source Human recombinant expressed in HEK-293 cells
• Control Compound 8-OH-DPAT Incubation Conditions: The reactions were carried out in 50 rnM TRIS-HCl (pH 7.4) containing 10 rnM MgSO 4 , 0.5 mM EDTA and 0.1% Ascorbic acid at room temperature for 1 hour. The reaction was terminated by rapid vacuum filtration onto glass fiber filters. Radioactivity trapped onto the filters was determined and compared to control values in order to ascertain any interactions of test compounds with the cloned serotonin- 5HT IA binding site (Literature Reference: Hoyer, D. et al. Eur. Journal Pharmacol. 1985, 118, 13-23; Schoeffter, P. and Hoyer, D. Naunyn-Schmiedeberg's Arch. Pharmac. 1989, 340, 135-138)
• Radioligand [ 3 H]-Ketanserin (60-90 Ci/mmol)
• 5HT 2 A binding site (Literature Reference: Leysen, J. E. et al. MoI. Pharmacol. 1982, 21, 301-
• radioligand binding assays for dopamine-D 2 s, serotonin-5HTiA and serotonin- 5HT 2A were carried out at six different concentrations and the test concentrations were 0.5 nM, 1 nM, 10 nm, 100 nM, 300 nM and 1000 nM.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Enzymes And Modification Thereof (AREA)
• Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42631516

Family Applications (2)

Family Applications Before (1)

Country Status (24)

Families Citing this family (14)

Citations (7)

Family Cites Families (35)

• 2010
  • 2010-02-26 PT PT107469496T patent/PT2400968T/pt unknown
  • 2010-02-26 WO PCT/US2010/025687 patent/WO2010099502A1/en not_active Ceased
  • 2010-02-26 ES ES10746949.6T patent/ES2605232T3/es active Active
  • 2010-02-26 US US12/714,406 patent/US8188076B2/en active Active
  • 2010-02-26 SG SG2011061223A patent/SG173842A1/en unknown
  • 2010-02-26 EP EP10746949.6A patent/EP2400968B1/en active Active
  • 2010-02-26 MX MX2011008885A patent/MX2011008885A/es active IP Right Grant
  • 2010-02-26 CN CN2010800192336A patent/CN102413830A/zh active Pending
  • 2010-02-26 US US12/714,407 patent/US8575185B2/en active Active
  • 2010-02-26 BR BRPI1009757A patent/BRPI1009757B1/pt active IP Right Grant
  • 2010-02-26 DK DK10746949.6T patent/DK2400968T3/da active
  • 2010-02-26 JP JP2011552210A patent/JP5337259B2/ja active Active
  • 2010-02-26 MY MYPI2011004047A patent/MY161473A/en unknown
  • 2010-02-26 AU AU2010217772A patent/AU2010217772B2/en active Active
  • 2010-02-26 UA UAA201111314A patent/UA102730C2/uk unknown
  • 2010-02-26 KR KR1020117022225A patent/KR101705727B1/ko active Active
  • 2010-02-26 PL PL10746949T patent/PL2400968T3/pl unknown
  • 2010-02-26 HU HUE10746949A patent/HUE031053T2/en unknown
  • 2010-02-26 WO PCT/US2010/025688 patent/WO2010099503A1/en not_active Ceased
  • 2010-02-26 CN CN201610463355.3A patent/CN106045936A/zh active Pending
  • 2010-02-26 RU RU2011139154/04A patent/RU2506262C2/ru active
  • 2010-02-26 CA CA2753599A patent/CA2753599C/en active Active
  • 2010-02-26 NZ NZ595263A patent/NZ595263A/xx not_active IP Right Cessation
• 2011
  • 2011-08-18 IL IL214754A patent/IL214754A/en active IP Right Grant
  • 2011-08-19 PH PH12011501669A patent/PH12011501669B1/en unknown
  • 2011-09-19 ZA ZA2011/06805A patent/ZA201106805B/en unknown
  • 2011-09-19 CO CO11121527A patent/CO6430428A2/es not_active Application Discontinuation
• 2012
  • 2012-05-07 US US13/465,439 patent/US8431570B2/en active Active
  • 2012-05-07 US US13/465,549 patent/US8461154B2/en active Active
• 2013
  • 2013-06-10 US US13/914,424 patent/US8859552B2/en active Active
• 2014
  • 2014-09-17 US US14/489,331 patent/US8980883B2/en active Active
• 2015
  • 2015-02-24 US US14/630,458 patent/US9255076B2/en active Active
• 2016
  • 2016-02-08 US US15/018,174 patent/US9604944B2/en active Active
• 2017
  • 2017-03-27 US US15/470,216 patent/US9975862B2/en active Active

Patent Citations (7)

Also Published As

Similar Documents

Legal Events